Pfizer is paying Innovent $650 million upfront to partner on cancer drug development, following Bristol Myers Squibb by striking a broad pact that positions Pfizer to leverage Chi ...

The pharmaceutical outfit has taken a savvy step forward. Now it just needs to repeat the process a few more times.

Pfizer (NYSE:PFE) reported breakthrough Phase 3 results for its BRAFTOVI combination in first-line metastatic colorectal cancer and TALZENNA combination in metastatic hormone-sensitive prostate cancer ...

Pfizer unveiled a multi-drug R&D collaboration with Innovent Biologics, making it the latest big pharma company to reach a ...

Pfizer PFE is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer medicines as well as a robust pipeline of cancer candidates with a focus on ...

Rigel Pharmaceuticals (RIGL) has cleared the final regulatory hurdle to secure the global rights for the breast cancer drug ...

At the time of this analysis, the Braftovi combination regimen with FOLFIRI and cetuximab demonstrated a clinically meaningful and statistically significant improvement in confirmed objective response ...

Pfizer Inc. (NYSE: PFE) on Tuesday shared news regarding its BRAFTOVI regimen for treating metastatic colorectal cancer. Pfizer announced that its Braftovi regimen demonstrated a statistically ...

The agreement covers eight early-stage trials from Innovent and four discovery programmes from global giant Pfizer China's ...

With COVID’s windfall over and blockbuster patents expiring, Pfizer is looking for a comeback with its newly built obesity ...